Immune modulation of human B lymphocytes by gene transfer with recombinant Epstein-Barr virus amplicons

Journal of Virological Methods

Volumn 72, Issue 1, 1998, Pages 81-93

  Wang, Fred ^a   Seldin, David C ^b   Annis, Bethany ^a   Trocha, Alicja ^c   Johnson, R Paul ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen presentation; Cytokine; Cytotoxic T cell; Epstein Barr virus; Gene transfer

Indexed keywords

GLYCOPROTEIN GP 120; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; VIRUS RECOMBINANT;

ANTIGEN PRESENTATION; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HUMANS; INTERLEUKIN-4; RECOMBINATION, GENETIC;

HUMAN HERPESVIRUS 4;

EID: 0031865609     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(98)00023-8     Document Type: Article

References (36)

1. Banerjee, S., Livanos, E., Vos, J.M., 1995. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus. Nat. Med. 1 (12), 1303-1308.
2. Baskar, S., 1996. Gene-modified tumor cells as cellular vaccine. Cancer Immunol. Immunother. 43 (3), 165-173.
3. Bornkamm, G.W., Hudewentz, J., Freese, U.K., Zimber, U., 1982. Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region. J. Virol. 43 (3), 952-968.
4. Cohen, J.I., Wang, F., Mannick, J., Kieff, E., 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. U.S.A. 86 (23), 9558-9562.
5. Erickson-Viitanen, S., Manfredi, J., Viitanen, P., Tribe, D.E., Tritch, R., Hutchison, C.D., Loeb, D.D., Swanstrom, R., Hutchison, C.A., 1989. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5 (6), 577-591.
6. Gardella, T., Medveczky, P., Sairenji, T., Mulder, C., 1984. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J. Virol. 50 (1), 248-254.
7. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., Pardoll, D.M., 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 (5032), 713-716.
8. Hammerschmidt, W., Sugden, B., 1988. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55 (3), 427-433.
9. Hammerschmidt, W., Sugden, B., 1989. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340 (6232), 393-397.
10. Hammond, S.A., Bollinger, R.C., Stanhope, P.E., Quinn, T.C., Schwartz, D., Clements, M.L., Siliciano, R.F., 1992. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4 + and CD8 + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 176 (6), 1531-1542.
11. Johnson, R.P., Trocha, A., Buchanan, T.M., Walker, B.D., 1992. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. Exp. Med. 175 (4), 961-971.
12. Johnson, R.P., Hammond, S.A., Trocha, A., Siliciano, R.F., Walker, B.D., 1994. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68 (5), 3145-3153.
13. Johnson, R.P., Trocha, A., Yang, L., Mazzara, G.P., Panicali, D.L., Buchanan, T.M., Walker, B.D., 1991. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147 (5), 1512-1521.
14. Kieff, E., 1996. Epstein-Barr virus and its replication. In: Knipe, D., Fields, B., Howley, P. (Eds.), Fields Virology. Raven Press, Philadelphia, pp. 2343-2396.
15. King, W., Dambaugh, T., Heller, M., Dowling, J., Kieff, E., 1982. Epstein-Barr virus DNA XII. A variable region of the Epstein-Barr virus genome is included in the P3HR-1 deletion. J. Virol. 43 (3), 979-986.
16. Lee, M.A., Kim, O.J., Yates, J.L., 1992. Targeted gene disruption in Epstein-Barr virus. Virology 189 (1), 253-265.
17. Lupton, S.D., Brunton, L.L., Kalberg, V.A., Overell, R.W., 1991. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Biol. Cell 11 (6), 3374-3378.
18. Miller, G., Shope, T., Lisco, H., Stitt, D., Lipman, M., 1972. Epstein-Barr virus: transformation, cytopathic changes and viral antigens in squirrel monkey and marmoset leukocytes. Proc. Natl. Acad. Sci. U.S.A. 69 (2), 383-387.
19. Miller, G., Robinson, J., Heston, L., Lipman, M., 1974. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference. Proc. Natl. Acad. Sci. U.S.A. 71 (10), 4006-4010.
20. Morrison, B.W., Leder, P., 1992. A receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis. J. Biol. Chem. 267 (17), 11957-11963.
21. Rabson, M., Gradoville, L., Heston, L., Miller, G., 1982. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J. Virol. 44 (3), 834-844.
22. Roome, A.J., Reading, C.L., 1984. The use of Epstein-Barr virus transformation for the production of human monoclonal antibodies. Exp. Biol. 43 (1), 35-55.
23. Scudiero, D.A., Shoemaker, R.H., Paull, K.D., Monks, A., Tierney, S., Nofziger, T.H., Currens, M.J., Seniff, D., Boyd, M.R., 1988. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48 (17), 4827-4833.
24. Seldin, D., Leder, P., 1994. Mutational analysis of a critical signaling domain of the human interleukin 4 receptor. Proc. Natl. Acad. Sci. U.S.A. 91, 2216-2220.
25. Shimizu, N., Yoshiyama, H., Takada, K., 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70 (10), 7260-7263.
26. Simons, J.W., Jaffee, E.M., Weber, C.E., Levitsky, H.I., Nelson, W.G., Carducci, M.A., Lazenby, A.J., Cohen, L.K., Finn, C.C., Clift, S.M., Hauda, K.M., Beck, L.A., Leiferman, K.M., Owens, A.H. Jr., Piantadosi, S., Dranoff, G., Mulligan, R.C., Pardoll, D.M., Marshall, F.F., 1997. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57 (8), 1537-1546.
27. Sodroski, J., Goh, W.C., Rosen, C., Campbell, K., Haseltine, W.A., 1986. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322 (6078), 470-474.
28. Steimer, K., Puma, J., Power, M., Poers, M., George-Nascimento, C., Stephans, J., Levy, J., Sanchez-Pescador, R., Luciw, P., Barr, P., Hallewell, R., 1986. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25 gag expressed in bacteria. Virology 150, 283-290.
29. Sun, T.Q., Livanos, E., Vos, J.M., 1996. Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes. Gene Ther. 3 (12), 1081-1088.
30. Tepper, R.I., Pattengale, P.K., Leder, P., 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57 (3), 503-512.
31. Tomkinson, B., Kieff, E., 1992. Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J. Virol. 66 (2), 780-789.
32. Tsomides, T., Aldovini, A., Johnson, R., Walker, B., Young, R., Eisen, H., 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180, 1283.
33. Walter, J.B., Brander, C., Mammen, M., Garbozi, D.N., Kalamas, S.A., Whitesides, G.M., Walker, B.D., Eisen, H.N., 1997. Stimulation of human cytotoxic T cells with HIV-1 derived peptides presented by recombinant HLA-A2 peptide complexes. Int. Immunol. 9 (3), 451-459.
34. Wang, F., Marchini, A., Kieff, E., 1991. Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells. J. Virol. 65 (4), 1701-1709.
35. Wang, F., Li, X., Annis, B., Faustman, D.L., 1995. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells. Hum. Gene Ther. 6 (8), 1005-1017.
36. Yates, J., Warren, N., Reisman, D., Sugden, B., 1984. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. U.S.A. 81 (12), 3806-3810.